What Plains GP Holders Bought Into

Plains GP had one headline move during this stretch that was hard to ignore. The business closed the sale of its Canadian NGL operations to Keyera and walked away with roughly $3.3b in cash after taxes and expenses. Investors who held Plains GP from the start of the year saw a total return of 44.7%, including dividends. If you were deciding on 1 January 2026, what did you need to believe about that planned exit and a more crude-focused future to support an investment in the stock?

This theme extends beyond Plains GP. See which of 43 power grid technology and infrastructure stocks may still merit a closer look.

The Two Plains GP Stories Investors Had To Weigh

The shares cost US$19.14 at the start of the period, and anyone looking at Plains GP then was really choosing between two competing futures.

The bullish narrative pointed to a Fair Value of US$21.54, a price implied by expectations that selling the NGL arm and reinvesting about US$3b into crude projects and buybacks would support higher margins and more predictable fee-based cash flows.

The bearish view anchored on a Fair Value of US$17.5 and focused on decarbonization risks, where tighter climate rules and weaker long term oil demand could restrict Permian pipeline use and raise the chance of stranded assets.

What The Plains GP Evidence Actually Tested

The closing of Plains GP’s Canadian NGL sale to Keyera, with about US$3.3b in net proceeds, clearly backed the exit-and-refocus plan that optimistic investors were watching. Management used much of that cash to reduce debt and tilt the portfolio toward crude. Reported results pulled the other way. Revenue grew from US$10,642m to US$17,693m, yet the business recorded a larger loss and net margin fell to 7.1%. The evidence cut both ways.

The decision on 1 January 2026 really hinged on one belief. You had to decide whether redeploying NGL cash into crude would outweigh any hit to profitability, which later results did not quickly confirm. For any other midstream stock, this can serve as a template. Track how asset sales, leverage and post-deal margins actually move after a portfolio reshape.

What Plains GP's Run Up Already Prices In

Plains GP now trades at US$26.62, after a 44.7% gain from the start of the year. The selected Narrative sees its Fair Value below that level. This reflects one interpretation of the risk and reward trade off rather than a statement of fact.

The thesis leans on steady energy transport and fee based contracts, but keeps circling back to crude exposure and Permian concentration. For today’s price to hold up, a buyer has to believe that crude throughput and regional volumes remain strong enough that decarbonization and regulatory pressure do not meaningfully erode long term pipeline utilization.

"Intensifying global decarbonization efforts and tightening climate policies threaten to decrease long-term demand for oil and gas, which could structurally reduce utilization of Plains GP Holdings' pipeline network, leading to declining volumes and significant pressure on revenue growth. Rapid adoption of electric vehicles and alternative fuels is set to erode transportation fuel consumption in key markets, diminishing the flow of crude oil through Plains' assets and further constraining top-line growth prospects."

One Narrative disagrees with today's price. → See where this Narrative says Plains GP should trade

Find Your Own Contrarian Opportunity

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

• Company 1 - 44% below our estimate - uses recent bank acquisitions and core system upgrades to pursue tighter efficiency.
• Company 2 - 41% below our estimate - ramps spending on AI, digital infrastructure and payments to expand future fee income sources.
• Company 3 - 34% below our estimate - advances late stage kidney, gene editing and endocrinology programs targeting therapies beyond cystic fibrosis.

Three companies from the same screener. Open the full list of 28 companies trading below our estimate →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com